ArticleIntegrative cancer therapies

Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.

Wenmin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.